We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!

RY 174.21 0.4845% TD 77.21 -0.3099% SHOP 113.1 0.5155% CNR 157.51 -1.1299% ENB 57.59 0.1565% CP 112.08 -0.5678% BMO 129.49 0.3332% TRI 232.87 0.7921% CNQ 49.045 1.1654% BN 76.23 1.3023% ATD 73.74 -0.6066% CSU 4426.6099 0.3812% BNS 73.69 -0.1896% CM 86.29 0.4657% SU 53.56 0.7714% TRP 65.64 0.845% NGT 78.23 1.1246% WCN 250.66 0.2239% MFC 42.08 -0.1898% BCE 46.14 0.2172%

Biosyent Inc.

Healthcare CA RX

11.11CAD
0.33(3.06%)

Last update at 2024-10-17T15:49:00Z

Day Range

11.1111.11
LowHigh

52 Week Range

6.969.26
LowHigh

Fundamentals

  • Previous Close 10.78
  • Market Cap98.79M
  • Volume100
  • P/E Ratio16.47
  • Dividend Yield1.89%
  • EBITDA7.55M
  • Revenue TTM30.78M
  • Revenue Per Share TTM2.56
  • Gross Profit TTM 22.86M
  • Diluted EPS TTM0.51

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 7.43M 8.38M 5.24M 5.87M 7.55M
Minority interest - - - - -
Net income 5.46M 6.28M 3.80M 4.37M 5.71M
Selling general administrative 15.28M 13.77M 11.58M 11.17M 9.67M
Selling and marketing expenses - - - - -
Gross profit 22.86M 22.64M 17.42M 16.65M 16.57M
Reconciled depreciation 0.45M 0.46M 0.51M 0.29M 0.19M
Ebit 6.98M 8.18M 5.03M 6.26M 6.86M
Ebitda 7.96M 8.92M 5.84M 6.19M 6.98M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 6.91M 8.25M 5.13M 5.39M 6.79M
Other operating expenses - - - - -
Interest expense 0.08M 0.09M 0.09M 0.03M 0.00000M
Tax provision 1.97M 2.10M 1.44M 1.50M 1.84M
Interest income 0.53M 0.14M 0.26M 0.45M 0.33M
Net interest income 0.45M 0.05M 0.17M 0.41M 0.33M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.97M 2.10M 1.44M 1.50M 1.84M
Total revenue 27.93M 28.62M 22.33M 21.42M 21.53M
Total operating expenses 21.02M 20.37M 17.21M 16.04M 14.73M
Cost of revenue 5.07M 5.98M 4.91M 4.78M 4.95M
Total other income expense net 0.08M 0.08M -0.05883M 0.07M 0.43M
Discontinued operations - - - - -
Net income from continuing ops 5.46M 6.28M 3.80M 4.37M 5.71M
Net income applicable to common shares 5.46M 6.28M 3.80M 4.37M 5.71M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 40.49M 37.17M 33.57M 30.97M 31.19M
Intangible assets 1.20M 0.87M 1.01M 1.02M 1.94M
Earning assets - - - - -
Other current assets - - - - 0.03M
Total liab 7.12M 5.61M 6.78M 5.17M 3.58M
Total stockholder equity 33.36M 31.55M 26.80M 25.79M 27.61M
Deferred long term liab 0.17M 0.12M 0.13M 0.07M 0.07M
Other current liab 0.48M 0.41M 1.26M 0.30M 0.43M
Common stock 5.37M 5.80M 6.39M 7.18M 7.65M
Capital stock 5.37M 5.80M 6.39M 7.18M 7.65M
Retained earnings 25.91M 24.12M 19.08M 17.48M 18.99M
Other liab 0.18M 0.08M 0.08M 0.10M 0.37M
Good will - - - - -
Other assets 0.64M 0.41M 0.76M 0.69M 0.69M
Cash 7.86M 18.04M 20.29M 13.44M 16.83M
Cash and equivalents - - - - -
Total current liabilities 5.72M 4.14M 5.14M 3.36M 3.21M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity -0.14314M -0.18526M -0.16670M -0.10530M -0.01473M
Property plant equipment 1.61M 1.85M 2.07M 2.36M 0.18M
Total current assets 37.14M 34.08M 29.77M 26.85M 28.35M
Long term investments - - - - -
Net tangible assets 32.27M 30.72M 25.83M 24.72M 25.64M
Short term investments 20.83M 10.18M 5.29M 8.53M 7.59M
Net receivables 3.66M 3.21M 1.82M 2.08M 2.12M
Long term debt - - - - -
Inventory 4.54M 2.20M 2.07M 2.14M 1.48M
Accounts payable 5.06M 3.56M 3.72M 2.92M 2.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 4.12M 2.84M
Deferred long term asset charges - - - - -
Non current assets total 3.34M 3.09M 3.80M 4.12M 2.84M
Capital lease obligations 1.40M 1.56M 1.71M 1.85M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -10.65469M -4.89011M 3.25M -0.93933M -0.90585M
Change to liabilities 1.35M -0.78116M 1.78M 0.11M 0.16M
Total cashflows from investing activities -10.79010M -4.83683M 3.39M -1.31569M -1.58487M
Net borrowings -0.16181M -0.15195M -0.14425M -0.02328M -0.02328M
Total cash from financing activities -4.37149M -2.07565M -3.37179M -6.38641M -0.50527M
Change to operating activities 0.20M -0.14844M 0.34M -0.34796M -0.15349M
Net income 5.46M 6.28M 3.80M 4.37M 5.71M
Change in cash -10.17072M -2.25615M 6.85M -3.39095M 4.18M
Begin period cash flow 18.04M 20.29M 13.44M 16.83M 12.65M
End period cash flow 7.86M 18.04M 20.29M 13.44M 16.83M
Total cash from operating activities 4.95M 4.67M 6.89M 4.40M 6.29M
Issuance of capital stock - - - - -
Depreciation 0.41M 0.42M 0.47M 0.24M 0.15M
Other cashflows from investing activities 0.19M 0.15M 0.32M 0.36M -0.17500M
Dividends paid 0.48M 0.48M 0.48M 0.48M -
Change to inventory -2.43701M -0.13077M 0.07M -0.65573M -0.57457M
Change to account receivables -0.42637M -0.96328M 0.21M 0.12M 0.05M
Sale purchase of stock -3.68866M -1.84877M -3.14201M -6.35160M -0.60619M
Other cashflows from financing activities -0.07714M -0.08525M -0.09294M -0.01625M -0.01625M
Change to netincome 0.13M 0.11M 0.09M 0.68M 0.91M
Capital expenditures 0.05M 0.08M 0.01M 0.50M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.09251M -2.17515M 2.53M -0.82688M -0.54699M
Stock based compensation 0.44M 0.33M 0.27M 0.26M -
Other non cash items -0.40491M -0.07619M -0.17865M - -
Free cash flow 4.43M 4.58M 6.72M 4.04M 5.78M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RX
Biosyent Inc.
0.33 3.06% 11.11 16.47 16.26 3.21 2.88 2.32 8.03
LOVE
Cannara Biotech Inc
- -% 0.64 10.00 - 1.26 0.90 1.98 7.20
DB
Decibel Cannabis Company Inc
- -% 0.05 - 3.38 0.48 1.17 0.87 39.48
LSL
LSL Pharma Group Inc.
- -% 0.45 - - 4.65 4.23 6.13 -14.2493
CANB
CanadaBis Capital Inc
- -% 0.05 8.33 - 1.51 4.30 1.69 6.60

Reports Covered

Stock Research & News

Profile

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Biosyent Inc.

2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1

Key Executives

Name Title Year Born
Mr. René C. Goehrum Chairman, CEO & Pres 1959
Mr. Robert J. March VP of Fin. & CFO NA
Mr. Joost van der Mark VP of Corp. Devel. NA
Ms. Neelu Atwal Director of HR NA
Mr. Alfred D'Souza Advisor NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.